Mogamulizumab

Mogamulizumab (Poteligeo®) is a prescription medicine used to treat adults with: • Cutaneous T-cell lymphoma (CTCL) that is: • Mycosis fungoides (MF) • Sézary syndrome (SS) Mogamulizumab is a type of medicine called a monoclonal antibody. It works by targeting a protein called CCR4 which is found on the surface of certain types of cancer cells. By targeting CCR4, mogamulizumab can help to slow the growth and spread of these cancer cells.

Mogamulizumab is a medication used to treat certain types of blood cancers, particularly those affecting T-lymphocytes (T-cells), a type of white blood cell. Here's a breakdown of its key features:

Function:

• Mogamulizumab belongs to a class of drugs called monoclonal antibodies. These are essentially engineered immune system proteins that can target specific cells.
• In the case of Mogamulizumab, it targets a protein called CCR4, which is found on the surface of some T-cell lymphomas. By attaching to CCR4, Mogamulizumab flags the cancer cells for destruction by the body's immune system.

Applications:

• Mogamulizumab is primarily approved for the treatment of:
  • Adult T-cell leukemia/lymphoma (ATL): A rare aggressive cancer of T-cells associated with Human T-lymphotropic virus type 1 (HTLV-1) infection.
  • Mycosis fungoides (MF) or Sézary syndrome (SS): Advanced stages of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma that affects the skin.
• It's typically used when other treatments haven't been successful.

Administration:

• Mogamulizumab is typically given as an intravenous (IV) infusion, meaning it's injected into a vein, usually over a course of hours. The dosage and frequency of treatment depend on the specific condition being treated.

Important Considerations:

• Mogamulizumab can cause side effects, including fever, chills, fatigue, skin rash, and infusion reactions. Serious side effects like immune system dysfunction and tumor lysis syndrome (rapid breakdown of cancer cells) can also occur in some cases.
• Mogamulizumab is a relatively new medication, and long-term effects are still being studied.
• It's not recommended for pregnant or breastfeeding women due to the potential risk to the developing baby.